TME-Related Biomimetic Strategies Against Cancer

References

• Brunetto E, De Monte L, Balzano G, et al. The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer. J Immunother Cancer. 2019;7(1):45. doi:10.1186/s40425-019-0521-4
   PubMedGoogle Scholar
• Melisi D, Garcia-Carbonero R, Macarulla T, et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br J Cancer. 2018;119(10):1208–1214. doi:10.1038/s41416-018-0246-z
   PubMed Web of Science ®Google Scholar
• Coulson R, Liew SH, Connelly AA, et al. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget. 2017;8(12):18640–18656. doi:10.18632/oncotarget.15553
   PubMedGoogle Scholar
• Jabłońska-Trypuć A, Matejczyk M, Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 2016;31(sup1):177–183. doi:10.3109/14756366.2016.1161620
   PubMed Web of Science ®Google Scholar
• Dinca SC, Greiner D, Weidenfeld K, Bond L, Barkan D, and Jorcyk CL. Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment. Breast Cancer Res. 2021;23(1):56. doi:10.1186/s13058-021-01430-x
   PubMed Web of Science ®Google Scholar
• De Vita A, Liverani C, Molinaro R, et al. Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer. Sci Rep. 2021;11(1):5107. doi:10.1038/s41598-021-84492-3
   PubMed Web of Science ®Google Scholar
• Röhrig F, Vorlová S, Hoffmann H, et al. VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors. Oncogene. 2017;36(1):1–12. doi:10.1038/onc.2016.182
   PubMed Web of Science ®Google Scholar
• Eatmann AI, Hamouda E, Hamouda H, et al. Potential use of thalidomide in glioblastoma treatment: an updated brief overview. Metabolites. 2023;13(4):543. doi:10.3390/metabo13040543
   PubMed Web of Science ®Google Scholar
• Naderi H, Matin MM, Bahrami AR. Review paper: critical issues in tissue engineering: biomaterials, cell sources, angiogenesis, and drug delivery systems. J Biomater Appl. 2011;26(4):383–417. doi:10.1177/0885328211408946
   PubMed Web of Science ®Google Scholar
• Beltrán-Partida E, Valdez-Salas B, García-López Portillo M, et al. Atherosclerotic-derived endothelial cell response conducted by titanium oxide nanotubes. Materials. 2023;16(2):794. doi:10.3390/ma16020794
   PubMed Web of Science ®Google Scholar
• Kim GH, Won JE, Byeon Y, et al. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. Drug Deliv. 2018;25(1):1394–1402. doi:10.1080/10717544.2018.1480672
   PubMed Web of Science ®Google Scholar
• Lv J, Wang S, Qiao D, Lin Y, Hu S, and Li M. Mitochondria-targeting multifunctional nanoplatform for cascade phototherapy and hypoxia-activated chemotherapy. J Nanobiotechnology. 2022;20(1):42. doi:10.1186/s12951-022-01244-9
   PubMed Web of Science ®Google Scholar
• Yang X, Zhao M, Wu Z, et al. Nano-ultrasonic contrast agent for chemoimmunotherapy of breast cancer by immune metabolism reprogramming and tumor autophagy. ACS Nano. 2022;16(2):3417–3431. doi:10.1021/acsnano.2c00462
   PubMed Web of Science ®Google Scholar
• Li X, Pan J, Li Y, et al. Development of a localized drug delivery system with a step-by-step cell internalization capacity for cancer immunotherapy. ACS Nano. 2022;16(4):5778–5794. doi:10.1021/acsnano.1c10892
   PubMed Web of Science ®Google Scholar
• Li Z, Ding Y, Liu J, et al. Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment. Nat Commun. 2022;13(1):1845. doi:10.1038/s41467-022-29388-0
   PubMed Web of Science ®Google Scholar
• Weber ANR, Bittner Z, Liu X, Dang TM, Radsak MP, and Brunner C. Bruton’s tyrosine kinase: an emerging key player in innate immunity. Front Immunol. 2017;8:1454. doi:10.3389/fimmu.2017.01454
   PubMed Web of Science ®Google Scholar
• Wang X, Ye L, He W, et al. In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma. J Control Release. 2022;345:786–797. doi:10.1016/j.jconrel.2022.03.050
   PubMed Web of Science ®Google Scholar
• Lee JA, Shin JM, Song SH, et al. Recruitment of dendritic cells using ‘find-me’ signaling microparticles for personalized cancer immunotherapy. Biomaterials. 2022;282:121412. doi:10.1016/j.biomaterials.2022.121412
   PubMed Web of Science ®Google Scholar
• Wang W, Xu H, Ye Q, et al. Systemic immune responses to irradiated tumours via the transport of antigens to the tumour periphery by injected flagellate bacteria. Nat Biomed Eng. 2022;6(1):44–53. doi:10.1038/s41551-021-00834-6
   PubMed Web of Science ®Google Scholar
• Yao H, Shen N, Ji G, et al. Cisplatin nanoparticles promote intratumoral CD8(+) T cell priming via antigen presentation and t cell receptor crosstalk. Nano Lett. 2022;22(8):3328–3339. doi:10.1021/acs.nanolett.2c00478
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang Y, Yang Y, et al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther. 2023;8(1):104. doi:10.1038/s41392-023-01365-z
   PubMed Web of Science ®Google Scholar
• Kim J, Kang S, Kim KW, et al. Nanoparticle delivery of recombinant IL-2 (BALLkine-2) achieves durable tumor control with less systemic adverse effects in cancer immunotherapy. Biomaterials. 2022;280:121257. doi:10.1016/j.biomaterials.2021.121257
   PubMed Web of Science ®Google Scholar
• Pei L, Liu Y, Liu L, et al. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22(1):29. doi:10.1186/s12943-023-01731-z
   PubMed Web of Science ®Google Scholar
• Linares J, Marín-Jiménez JA, Badia-Ramentol J, and Calon A. Determinants and Functions of CAFs secretome during cancer progression and therapy. Front Cell Dev Biol. 2020;8:621070. doi:10.3389/fcell.2020.621070
   PubMed Web of Science ®Google Scholar
• Komohara Y, Takeya M. CAFs and TAMs: maestros of the tumour microenvironment. J Pathol. 2017;241(3):313–315. doi:10.1002/path.4824
   PubMed Web of Science ®Google Scholar
• Ding Z, Shi R, Hu W, et al. Cancer-associated fibroblasts in hematologic malignancies: elucidating roles and spotlighting therapeutic targets. Front Oncol. 2023;13:1193978. doi:10.3389/fonc.2023.1193978
   PubMed Web of Science ®Google Scholar
• Saw PE, Chen J, Song E. Targeting CAFs to overcome anticancer therapeutic resistance. Trends Cancer. 2022;8(7):527–555. doi:10.1016/j.trecan.2022.03.001
   PubMed Web of Science ®Google Scholar
• Geng X, Chen H, Zhao L, et al. Cancer-Associated Fibroblast (CAF) heterogeneity and targeting therapy of CAFs in pancreatic cancer. Front Cell Dev Biol. 2021;9:655152. doi:10.3389/fcell.2021.655152
   PubMed Web of Science ®Google Scholar
• De P, Aske J, Sulaiman R, Dey N. Bête noire of chemotherapy and targeted therapy: CAF-Mediated resistance. Cancers. 2022;14(6). doi:10.3390/cancers14061519
   Web of Science ®Google Scholar
• Barcus CE, Hwang PY, Morikis V, et al. Tyrosine kinase-independent actions of DDR2 in tumor cells and cancer-associated fibroblasts influence tumor invasion, migration and metastasis. J Cell Sci. 2021;134(19). doi:10.1242/jcs.258431
   PubMed Web of Science ®Google Scholar
• Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921–R925. doi:10.1016/j.cub.2020.06.081
   PubMed Web of Science ®Google Scholar
• Arneth B. Tumor Microenvironment. Medicina. 2019;56(1). doi:10.3390/medicina56010015
   PubMed Web of Science ®Google Scholar
• Seewaldt V. ECM stiffness paves the way for tumor cells. Nat Med. 2014;20(4):332–333. doi:10.1038/nm.3523
   PubMed Web of Science ®Google Scholar
• Graf F, Horn P, Ho AD, Boutros M, and Maercker C. The extracellular matrix proteins type I collagen, type III collagen, fibronectin, and laminin 421 stimulate migration of cancer cells. FASEB j. 2021;35(7):e21692. doi:10.1096/fj.202002558RR
   PubMed Web of Science ®Google Scholar
• Di Martino JS, Akhter T, Bravo-Cordero JJ. Remodeling the ECM: implications for metastasis and tumor dormancy. Cancers. 2021;13(19):4916. doi:10.3390/cancers13194916
   PubMed Web of Science ®Google Scholar
• Bao Y, Wang L, Shi L, et al. Transcriptome profiling revealed multiple genes and ECM-receptor interaction pathways that may be associated with breast cancer. Cell Mol Biol Lett. 2019;24:38. doi:10.1186/s11658-019-0162-0
   PubMed Web of Science ®Google Scholar
• Schedin P, Keely PJ. Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. Cold Spring Harb Perspect Biol. 2011;3(1):a003228–a003228. doi:10.1101/cshperspect.a003228
   PubMed Web of Science ®Google Scholar
• Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol. 2012;5:63. doi:10.1186/1756-8722-5-63
   PubMed Web of Science ®Google Scholar
• Park J, Lee H, Tran Q, et al. Recognition of transmembrane protein 39A as a tumor-specific marker in brain tumor. Toxicol Res. 2017;33(1):63–69. doi:10.5487/TR.2017.33.1.063
   PubMedGoogle Scholar
• Sánchez Ramírez J, Morera Díaz Y, Bequet-Romero M, et al. Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program. BMC Immunol. 2020;21(1):12. doi:10.1186/s12865-020-0338-4
   PubMed Web of Science ®Google Scholar
• Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019;18(1):14. doi:10.1186/s12943-018-0927-5
   PubMed Web of Science ®Google Scholar
• Kim MY, Shin JY, Kim JO, et al. Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma. BMC Cancer. 2020;20(1):1057. doi:10.1186/s12885-020-07566-x
   PubMed Web of Science ®Google Scholar
• Carson-Walter EB, Winans BN, Whiteman MC, et al. Characterization of TEM1/endosialin in human and murine brain tumors. BMC Cancer. 2009;9:417. doi:10.1186/1471-2407-9-417
   PubMed Web of Science ®Google Scholar
• Lee N, Yoo D, Ling D, Cho MH, Hyeon T, and Cheon J. Iron oxide based nanoparticles for multimodal imaging and magnetoresponsive therapy. Chem Rev. 2015;115(19):10637–10689. doi:10.1021/acs.chemrev.5b00112
   PubMed Web of Science ®Google Scholar
• Joyce CE, Zhou X, Xia J, et al. Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet. 2011;20(20):4025–4040. doi:10.1093/hmg/ddr331
   PubMed Web of Science ®Google Scholar
• Choi YS, Jang H, Gupta B, et al. Tie2-mediated vascular remodeling by ferritin-based protein C nanoparticles confers antitumor and anti-metastatic activities. J Hematol Oncol. 2020;13(1):123. doi:10.1186/s13045-020-00952-9
   PubMed Web of Science ®Google Scholar
• Emoto M, Naganuma Y, Choijamts B, et al. Novel chemoembolization using calcium-phosphate ceramic microsphere incorporating TNP-470, an anti-angiogenic agent. Cancer Sci. 2010;101(4):984–990. doi:10.1111/j.1349-7006.2009.01479.x
   PubMed Web of Science ®Google Scholar
• Hossain MA, Liu G, Dai B, et al. Reinvigorating exhausted CD8(+) cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Med Res Rev. 2021;41(1):156–201. doi:10.1002/med.21727
   PubMed Web of Science ®Google Scholar
• Bejarano L, Jordāo MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933–959. doi:10.1158/2159-8290.CD-20-1808
   PubMed Web of Science ®Google Scholar
• Tsai MJ, Chang WA, Huang MS, and Kuo PL. Tumor microenvironment: a new treatment target for cancer. ISRN Biochem. 2014;2014:351959. doi:10.1155/2014/351959
   PubMedGoogle Scholar
• Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753. doi:10.1016/j.pharmthera.2020.107753
   PubMed Web of Science ®Google Scholar
• Gocher AM, Workman CJ, Vignali DAA. Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22(3):158–172. doi:10.1038/s41577-021-00566-3
   PubMed Web of Science ®Google Scholar
• Pagano E, Elias JE, Schneditz G, et al. Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment. Gut. 2022;71(3):509–520. doi:10.1136/gutjnl-2020-323363
   PubMed Web of Science ®Google Scholar
• Borriello L, Coste A, Traub B, et al. Primary tumor associated macrophages activate programs of invasion and dormancy in disseminating tumor cells. Nat Commun. 2022;13(1):626. doi:10.1038/s41467-022-28076-3
   PubMed Web of Science ®Google Scholar
• Yang M, Li J, Gu P, and Fan X. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioact Mater. 2021;6(7):1973–1987. doi:10.1016/j.bioactmat.2020.12.010
   PubMed Web of Science ®Google Scholar
• Müller AK, Köhler UA, Trzebanski S, et al. Mouse modeling dissecting macrophage-breast cancer communication uncovered roles of PYK2 in macrophage recruitment and breast tumorigenesis. Adv Sci. 2022;9(9):e2105696. doi:10.1002/advs.202105696
   Web of Science ®Google Scholar
• Hu M, Huang L. Strategies targeting tumor immune and stromal microenvironment and their clinical relevance. Adv Drug Deliv Rev. 2022;183:114137. doi:10.1016/j.addr.2022.114137
   PubMed Web of Science ®Google Scholar
• Guo R, Wang S, Zhao L, et al. Engineered nanomaterials for synergistic photo-immunotherapy. Biomaterials. 2022;282:121425. doi:10.1016/j.biomaterials.2022.121425
   PubMed Web of Science ®Google Scholar
• Huang TX, Tan XY, Huang HS, et al. Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut. 2022;71(2):333–344. doi:10.1136/gutjnl-2020-322924
   PubMed Web of Science ®Google Scholar
• Cheung PF, Yang J, Fang R, et al. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Nat Commun. 2022;13(1):156. doi:10.1038/s41467-021-27088-9
   PubMedGoogle Scholar
• Duong E, Fessenden TB, Lutz E, et al. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Immunity. 2022;55(2):308–323.e309. doi:10.1016/j.immuni.2021.10.020
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Kryza T, Batra J, and Clements J. Remodelling of the tumour microenvironment by the kallikrein-related peptidases. Nat Rev Cancer. 2022;22(4):223–238. doi:10.1038/s41568-021-00436-z
   PubMed Web of Science ®Google Scholar
• Downs-Canner SM, Meier J, Vincent BG, and Serody JS. B cell function in the tumor microenvironment. Annu Rev Immunol. 2022;40:169–193. doi:10.1146/annurev-immunol-101220-015603
   PubMed Web of Science ®Google Scholar
• Kang JH, Zappasodi R. Modulating Treg stability to improve cancer immunotherapy. Trends Cancer. 2023;9(11):911–927. doi:10.1016/j.trecan.2023.07.015
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Sancho E, Batlle E. Overcoming TGFβ-mediated immune evasion in cancer. Nat Rev Cancer. 2022;22(1):25–44. doi:10.1038/s41568-021-00413-6
   PubMed Web of Science ®Google Scholar
• Gavrielatou N, Vathiotis I, Economopoulou P, and Psyrri A. The role of B cells in head and neck cancer. Cancers. 2021;13(21):5383. doi:10.3390/cancers13215383
   PubMed Web of Science ®Google Scholar
• Biber G, Sabag B, Raiff A, et al. Modulation of intrinsic inhibitory checkpoints using nano-carriers to unleash NK cell activity. EMBO Mol Med. 2022;14(1):e14073. doi:10.15252/emmm.202114073
   PubMed Web of Science ®Google Scholar
• Hu W, Wang G, Huang D, Sui M, and Xu Y. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front Immunol. 2019;10:1205. doi:10.3389/fimmu.2019.01205
   PubMed Web of Science ®Google Scholar
• Tong L, Jiménez-Cortegana C, Tay AHM, Wickström S, Galluzzi L, and Lundqvist A. NK cells and solid tumors: therapeutic potential and persisting obstacles. Mol Cancer. 2022;21(1):206. doi:10.1186/s12943-022-01672-z
   PubMed Web of Science ®Google Scholar
• Liu H, Wang Z, Zhou Y, and Yang Y. MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target. Front Immunol. 2023;14:1199273. doi:10.3389/fimmu.2023.1199273
   PubMed Web of Science ®Google Scholar
• Li K, Shi H, Zhang B, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6(1):362. doi:10.1038/s41392-021-00670-9
   PubMed Web of Science ®Google Scholar
• Hei Y, Chen Y, Li Q, et al. Multifunctional immunoliposomes enhance the immunotherapeutic effects of PD-L1 antibodies against melanoma by reprogramming immunosuppressive tumor microenvironment. Small. 2022;18(9):e2105118. doi:10.1002/smll.202105118
   PubMed Web of Science ®Google Scholar
• Zhai Q, Chen Y, Xu J, et al. Lymphoma immunochemotherapy: targeted delivery of doxorubicin via a dual functional nanocarrier. Mol Pharm. 2017;14(11):3888–3895. doi:10.1021/acs.molpharmaceut.7b00606
   PubMedGoogle Scholar
• Rattan R, Bhattacharjee S, Zong H, et al. Nanoparticle-macrophage interactions: a balance between clearance and cell-specific targeting. Bioorg Med Chem. 2017;25(16):4487–4496. doi:10.1016/j.bmc.2017.06.040
   PubMed Web of Science ®Google Scholar
• Fang RH, Jiang Y, Fang JC, and Zhang L. Cell membrane-derived nanomaterials for biomedical applications. Biomaterials. 2017;128:69–83. doi:10.1016/j.biomaterials.2017.02.041
   PubMed Web of Science ®Google Scholar
• Vandchali NR, Moadab F, Taghizadeh E, Tajbakhsh A, and Gheibihayat SM. CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) alternative: a novel approach to improve drug delivery. Curr Drug Targets. 2021;22(15):1750–1759. doi:10.2174/1389450122666210204203514
   PubMed Web of Science ®Google Scholar
• Jalil AR, Tobin MP, Discher DE. Suppressing or enhancing macrophage engulfment through the use of CD47 and related peptides. Bioconjug Chem. 2022;33(11):1989–1995. doi:10.1021/acs.bioconjchem.2c00019
   PubMed Web of Science ®Google Scholar
• Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, and Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A. 2011;108(27):10980–10985. doi:10.1073/pnas.1106634108
   PubMed Web of Science ®Google Scholar
• Gheibi Hayat SM, Bianconi V, Pirro M, and Sahebkar A. Stealth functionalization of biomaterials and nanoparticles by CD47 mimicry. Int J Pharm. 2019;569:118628. doi:10.1016/j.ijpharm.2019.118628
   PubMed Web of Science ®Google Scholar
• Pei Q, Hu X, Zheng X, et al. Light-activatable red blood cell membrane-camouflaged dimeric prodrug nanoparticles for synergistic photodynamic/chemotherapy. ACS Nano. 2018;12(2):1630–1641. doi:10.1021/acsnano.7b08219
   PubMed Web of Science ®Google Scholar
• Liu H, Su YY, Jiang XC, and Gao JQ. Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system. Drug Deliv Transl Res. 2023;13(3):716–737. doi:10.1007/s13346-022-01252-0
   PubMed Web of Science ®Google Scholar
• Han Y, Gao C, Wang H, et al.Corrigendum to ”Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer’s disease mice. Bioact Mater. 2022;(7):73. doi:10.1016/j.bioactmat.2021.06.002
   PubMedGoogle Scholar
• Hu T, Huang Y, Liu J, Shen C, Wu F, and He Z. Biomimetic cell-derived nanoparticles: emerging platforms for cancer immunotherapy. Pharmaceutics. 2023;15(7):1821. doi:10.3390/pharmaceutics15071821
   PubMed Web of Science ®Google Scholar
• Fang RH, Hu CM, Luk BT, et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14(4):2181–2188. doi:10.1021/nl500618u
   PubMed Web of Science ®Google Scholar
• Wu Z, Zhang H, Yan J, Wei Y, and Su J. Engineered biomembrane-derived nanoparticles for nanoscale theranostics. Theranostics. 2023;13(1):20–39. doi:10.7150/thno.76894
   PubMed Web of Science ®Google Scholar
• Li S, Wu Y, Ding F, et al. Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer. Nanoscale. 2020;12(19):10854–10862. doi:10.1039/D0NR00523A
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang H, Gu J, et al. Engineered extracellular vesicles for cancer therapy. Adv Mater. 2021;33:14.
   Web of Science ®Google Scholar
• Smyth T, Kullberg M, Malik N, Smith-Jones P, Graner MW, and Anchordoquy TJ. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J Control Release. 2015;199:145–155. doi:10.1016/j.jconrel.2014.12.013
   PubMed Web of Science ®Google Scholar
• Xu M, Feng T, Liu B, et al. Engineered exosomes: desirable target-tracking characteristics for cerebrovascular and neurodegenerative disease therapies. Theranostics. 2021;11(18):8926–8944. doi:10.7150/thno.62330
   PubMed Web of Science ®Google Scholar
• Zhang M, Hu S, Liu L, et al. Engineered exosomes from different sources for cancer-targeted therapy. Signal Transduct Target Ther. 2023;8(1):124. doi:10.1038/s41392-023-01382-y
   PubMed Web of Science ®Google Scholar
• Xie H, Li W, Liu H, et al. Erythrocyte membrane-coated invisible acoustic-sensitive nanoparticle for inducing tumor thrombotic infarction by precisely damaging tumor vascular endothelium. Small. 2022;18(30):e2201933. doi:10.1002/smll.202201933
   PubMed Web of Science ®Google Scholar
• Rao L, Bu LL, Xu JH, et al. Red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance. Small. 2015;11(46):6225–6236. doi:10.1002/smll.201502388
   PubMed Web of Science ®Google Scholar
• Liu T, Shi C, Duan L, et al. A highly hemocompatible erythrocyte membrane-coated ultrasmall selenium nanosystem for simultaneous cancer radiosensitization and precise antiangiogenesis. J Mater Chem B. 2018;6(29):4756–4764. doi:10.1039/C8TB01398E
   PubMed Web of Science ®Google Scholar
• Liang X, Ye X, Wang C, et al. Photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation. J Control Release. 2019;296:150–161. doi:10.1016/j.jconrel.2019.01.027
   PubMed Web of Science ®Google Scholar
• Ren H, Liu J, Li Y, et al. Oxygen self-enriched nanoparticles functionalized with erythrocyte membranes for long circulation and enhanced phototherapy. Acta Biomater. 2017;59:269–282. doi:10.1016/j.actbio.2017.06.035
   PubMed Web of Science ®Google Scholar
• Chen Q, Zhang L, Li L, et al. Cancer cell membrane-coated nanoparticles for bimodal imaging-guided photothermal therapy and docetaxel-enhanced immunotherapy against cancer. J Nanobiotechnology. 2021;19(1):449. doi:10.1186/s12951-021-01202-x
   PubMed Web of Science ®Google Scholar
• Park W, Seong KY, Han HH, Yang SY, and Hahn SK. Dissolving microneedles delivering cancer cell membrane coated nanoparticles for cancer immunotherapy. RSC Adv. 2021;11(17):10393–10399. doi:10.1039/D1RA00747E
   PubMed Web of Science ®Google Scholar
• Gan J, Du G, He C, et al. Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination. J Control Release. 2020;326:297–309. doi:10.1016/j.jconrel.2020.07.008
   PubMed Web of Science ®Google Scholar
• Li Z, Cai H, Li Z, et al. A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody. Bioact Mater. 2023;21:299–312. doi:10.1016/j.bioactmat.2022.08.028
   PubMed Web of Science ®Google Scholar
• Jin J, Krishnamachary B, Barnett JD, et al. Human cancer cell membrane-coated biomimetic nanoparticles reduce fibroblast-mediated invasion and metastasis and induce T-cells. ACS Appl Mater Interfaces. 2019;11(8):7850–7861. doi:10.1021/acsami.8b22309
   PubMed Web of Science ®Google Scholar
• Molinaro R, Martinez JO, Zinger A, et al. Leukocyte-mimicking nanovesicles for effective doxorubicin delivery to treat breast cancer and melanoma. Biomater Sci. 2020;8(1):333–341. doi:10.1039/C9BM01766F
   PubMed Web of Science ®Google Scholar
• Chen C, Song M, Du Y, et al. Tumor-associated-macrophage-membrane-coated nanoparticles for improved photodynamic immunotherapy. Nano Lett. 2021;21(13):5522–5531. doi:10.1021/acs.nanolett.1c00818
   PubMed Web of Science ®Google Scholar
• Cao X, Tan T, Zhu D, et al. Paclitaxel-loaded macrophage membrane camouflaged albumin nanoparticles for targeted cancer therapy. Int J Nanomed. 2020;15:1915–1928. doi:10.2147/IJN.S244849
   PubMed Web of Science ®Google Scholar
• Huang X, Wang L, Guo H, and Zhang W. Macrophage membrane-coated nanovesicles for dual-targeted drug delivery to inhibit tumor and induce macrophage polarization. Bioact Mater. 2023;23:69–79. doi:10.1016/j.bioactmat.2022.09.027
   PubMed Web of Science ®Google Scholar
• Yin T, Fan Q, Hu F, et al. Engineered macrophage-membrane-coated nanoparticles with enhanced PD-1 expression induce immunomodulation for a synergistic and targeted antiglioblastoma activity. Nano Lett. 2022;22(16):6606–6614. doi:10.1021/acs.nanolett.2c01863
   PubMed Web of Science ®Google Scholar
• Pitchaimani A, Nguyen TDT, Aryal S. Natural killer cell membrane infused biomimetic liposomes for targeted tumor therapy. Biomaterials. 2018;160:124–137. doi:10.1016/j.biomaterials.2018.01.018
   PubMed Web of Science ®Google Scholar
• Cao X, Hu Y, Luo S, et al. Neutrophil-mimicking therapeutic nanoparticles for targeted chemotherapy of pancreatic carcinoma. Acta Pharm Sin B. 2019;9(3):575–589. doi:10.1016/j.apsb.2018.12.009
   PubMed Web of Science ®Google Scholar
• Zhao J, Lu H, Xu D, et al. Neutrophil membrane-coated nanoparticles for enhanced nanosecond pulsed electric field treatment of pancreatic cancer. Int J Hyperthermia. 2022;39(1):1026–1035. doi:10.1080/02656736.2022.2093994
   PubMed Web of Science ®Google Scholar
• Wang H, Wu J, Williams GR, et al. Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery. J Nanobiotechnology. 2019;17(1):60. doi:10.1186/s12951-019-0494-y
   PubMedGoogle Scholar
• Jiang Q, Wang K, Zhang X, et al. Platelet membrane‐camouflaged magnetic nanoparticles for ferroptosis‐enhanced cancer immunotherapy. Small. 2020;16(22):e2001704. doi: 10.1002/smll.202001704
   Web of Science ®Google Scholar
• Wang C, Sun W, Ye Y, Hu Q, Bomba HN, and Gu Z. In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. Nat Biomed Eng. 2017;1(2):0011. doi:10.1038/s41551-016-0011
   Web of Science ®Google Scholar
• Li B, Chu T, Wei J, et al. Platelet-membrane-coated nanoparticles enable vascular disrupting agent combining anti-angiogenic drug for improved tumor vessel impairment. Nano Lett. 2021;21(6):2588–2595. doi:10.1021/acs.nanolett.1c00168
   PubMed Web of Science ®Google Scholar
• Luo X, Cao J, Yu J, et al. Regulating acidosis and relieving hypoxia by platelet membrane-coated nanoparticle for enhancing tumor chemotherapy. Front Bioeng Biotechnol. 2022;10:885105. doi:10.3389/fbioe.2022.885105
   PubMed Web of Science ®Google Scholar
• Dehaini D, Wei X, Fang RH, et al. Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv Mater. 2017;29(16). doi:10.1002/adma.201606209
   Web of Science ®Google Scholar
• Gong C, Yu X, Zhang W, et al. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles. J Nanobiotechnology. 2021;19(1):58. doi:10.1186/s12951-021-00805-8
   PubMed Web of Science ®Google Scholar
• Gong C, Yu X, You B, et al. Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy. J Nanobiotechnology. 2020;18(1):92. doi:10.1186/s12951-020-00649-8
   PubMed Web of Science ®Google Scholar
• Wang Y, Luan Z, Zhao C, Bai C, and Yang K. Target delivery selective CSF-1R inhibitor to tumor-associated macrophages via erythrocyte-cancer cell hybrid membrane camouflaged pH-responsive copolymer micelle for cancer immunotherapy. Eur J Pharm Sci. 2020;142:105136. doi:10.1016/j.ejps.2019.105136
   PubMed Web of Science ®Google Scholar
• Feng J, Xiang L, Fang C, et al. Dual-targeting of tumor cells and tumor-associated macrophages by palmitic acid modified albumin nanoparticles for antitumor and antimetastasis therapy. ACS Appl Mater Interfaces. 2022;14(13):14887–14902. doi:10.1021/acsami.1c23274
   PubMed Web of Science ®Google Scholar
• Wang X, Liu Y, Xue C, et al. A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses. Nat Commun. 2022;13(1):5685. doi:10.1038/s41467-022-33301-0
   PubMed Web of Science ®Google Scholar
• Rabie EM, Zhang SX, Kourouklis AP, et al. Matrix degradation and cell proliferation are coupled to promote invasion and escape from an engineered human breast microtumor. Integr Biol. 2021;13(1):17–29. doi:10.1093/intbio/zyaa026
   Google Scholar
• Chen B, Dong X, Dong X, et al. Integration of dual targeting and dual therapeutic modules endows self-assembled nanoparticles with anti-tumor growth and metastasis functions. Int J Nanomed. 2021;16:1361–1376. doi:10.2147/IJN.S291285
   PubMed Web of Science ®Google Scholar
• Mine Y, Munir H, Nakanishi Y, and Sugiyama D. Biomimetic peptides for the treatment of cancer. Anticancer Res. 2016;36(7):3565–3570.
   PubMed Web of Science ®Google Scholar
• Wang S, Blois A, El Rayes T, et al. Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Sci Transl Med. 2016;8(329):329ra334. doi:10.1126/scitranslmed.aad5653
   Web of Science ®Google Scholar
• Xiang Y, Chen L, Zhou R, and Huang Y. Enhanced intracellular and intranuclear drug delivery mediated by biomimetic peptide SVS-1 for anticancer therapy. Int J Pharm. 2019;570:118668. doi:10.1016/j.ijpharm.2019.118668
   PubMedGoogle Scholar
• Qing S, Lyu C, Zhu L, et al. Biomineralized bacterial outer membrane vesicles potentiate safe and efficient tumor microenvironment reprogramming for anticancer therapy. Adv Mater. 2020;32:47.
   Web of Science ®Google Scholar
• Nie W, Yu T, Liu X, et al. Non-viral vector mediated CKb11 with folic acid modification regulates macrophage polarization and DC maturation to elicit immune response against cancer. Bioact Mater. 2021;6(11):3678–3691. doi:10.1016/j.bioactmat.2021.03.031
   PubMed Web of Science ®Google Scholar
• Lu Y, Li L, Du J, et al. Immunotherapy for tumor metastasis by artificial antigen-presenting cells via targeted microenvironment regulation and T-Cell activation. ACS Appl Mater Interfaces. 2021;13(47):55890–55901. doi:10.1021/acsami.1c17498
   PubMed Web of Science ®Google Scholar
• Song Y, Xu M, Li Y, et al. An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy. Int J Pharm. 2020;586:119498. doi:10.1016/j.ijpharm.2020.119498
   PubMedGoogle Scholar
• Kim M, Lee JS, Kim W, et al. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. J Control Release. 2022;348:893–910. doi:10.1016/j.jconrel.2022.06.039
   PubMed Web of Science ®Google Scholar
• Chen Q, Li Q, Liang Y, et al. Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer via ROS generation and microbiota modulation. Acta Pharm Sin B. 2022;12(2):907–923. doi:10.1016/j.apsb.2021.08.016
   PubMed Web of Science ®Google Scholar
• Hu M, Zhang J, Kong L, et al. Immunogenic hybrid nanovesicles of liposomes and tumor-derived nanovesicles for cancer immunochemotherapy. ACS Nano. 2021;15(2):3123–3138. doi:10.1021/acsnano.0c09681
   PubMed Web of Science ®Google Scholar
• Hu XX, He PP, Qi GB, et al. Transformable nanomaterials as an artificial extracellular matrix for inhibiting tumor invasion and metastasis. ACS Nano. 2017;11(4):4086–4096. doi:10.1021/acsnano.7b00781
   PubMed Web of Science ®Google Scholar
• Zheng DW, Hong S, Zhang QL, et al. Controllable gelation of artificial extracellular matrix for altering mass transport and improving cancer therapies. Nat Commun. 2020;11(1):4907. doi:10.1038/s41467-020-18493-7
   PubMed Web of Science ®Google Scholar
• Vairavel M, Devaraj E, Shanmugam R. An eco-friendly synthesis of Enterococcus sp.-mediated gold nanoparticle induces cytotoxicity in human colorectal cancer cells. Environ Sci Pollut Res Int. 2020;27(8):8166–8175. doi:10.1007/s11356-019-07511-x
   PubMed Web of Science ®Google Scholar
• Selvanesan BC, Chandra D, Quispe-Tintaya W, et al. Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice. Sci Transl Med. 2022;14(637):eabc1600. doi:10.1126/scitranslmed.abc1600
   PubMed Web of Science ®Google Scholar